New and Future Parenteral Therapies for the Management of Lipid Disorders.

Affiliation

Piedmont Heart Institute in Atlanta, Atlanta, GA, USA. Electronic address: [Email]

Abstract

Cardiovascular disease (CVD) is the leading cause of death in the world. According to the World Health Organization, an estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 5% are due to myocardial infarction and stroke. Dyslipidemia is known as the major risk factor of atherosclerotic cardiovascular disease. With current therapies, about 60% of high-risk CVD patients do not achieve LDL-C goals, and in patients with familiar hypercholesterolemia (FH) at maximum intensity statin treatment, only 20% achieve LDL-C goals. We discuss new and future parenteral therapies for the management of lipid disorders.

Keywords

Alipogene,Antisense oligonucleotides,Cardiovascular disease,Dyslipidemia,Inclinsiran,LDL,Lipid disorders therapy,PCSK9,sIRNA,

OUR Recent Articles